338 related articles for article (PubMed ID: 34474712)
1. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities.
Spergel JM; Blaiss MS; Lio P; Kessel A; Cantrell WC; Takiya L; Werth JL; O'Connell MA; Zang C; Cork MJ
Allergy Asthma Proc; 2021 Sep; 42(5):425-431. PubMed ID: 34474712
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
[TBL] [Abstract][Full Text] [Related]
3. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
[TBL] [Abstract][Full Text] [Related]
4. Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
Luger TA; Hebert AA; Zaenglein AL; Silverberg JI; Tan H; Ports WC; Zielinski MA
Paediatr Drugs; 2022 Mar; 24(2):175-183. PubMed ID: 35292919
[TBL] [Abstract][Full Text] [Related]
5. Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis.
Eichenfield LF; Yosipovitch G; Stein Gold LF; Kalabis M; Zang C; Vlahos B; Sanders P; Myers DE; Bushmakin AG; Cappelleri JC; Olivadoti M; Paller AS
Pediatr Dermatol; 2020 Nov; 37(6):1030-1037. PubMed ID: 32981097
[TBL] [Abstract][Full Text] [Related]
6. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
Schlessinger J; Shepard JS; Gower R; Su JC; Lynde C; Cha A; Ports WC; Purohit V; Takiya L; Werth JL; Zang C; Vlahos B;
Am J Clin Dermatol; 2020 Apr; 21(2):275-284. PubMed ID: 32212104
[TBL] [Abstract][Full Text] [Related]
7. A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis.
Fujita K; Yagi M; Moriwaki S; Yoshida M; Graham D
J Dermatol; 2021 Nov; 48(11):1640-1651. PubMed ID: 34435694
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis.
Eichenfield LF; Stein Gold LF; Lynde C; Guenther L; Greenberger S; Chu CY; Ghodsi Z; Vlahos B; Sanders P; Cha A; Canosa JM
Dermatol Ther (Heidelb); 2024 Apr; 14(4):875-892. PubMed ID: 38546803
[TBL] [Abstract][Full Text] [Related]
9. Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis.
Stein Gold LF; Tom WL; Shi V; Sanders P; Zang C; Vlahos B; Cha A
Dermatitis; 2024; 35(1):84-91. PubMed ID: 38206678
[No Abstract] [Full Text] [Related]
10. Demographics and Baseline Disease Characteristics of Early Responders to Crisaborole for Atopic Dermatitis.
Stein Gold LF; Takiya L; Zang C; Sanders P; Feldman SR
J Drugs Dermatol; 2020 Jun; 19(6):619-624. PubMed ID: 32574023
[TBL] [Abstract][Full Text] [Related]
11. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
Ahmed A; Solman L; Williams HC
Br J Dermatol; 2018 Mar; 178(3):659-662. PubMed ID: 29205284
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis.
Ma L; Zhang L; Kobayashi M; Tao X; Qian Q; Cheng H; Liu S; Zhou Y; Chen Y; Zhang J
J Dermatol; 2023 Jul; 50(7):847-855. PubMed ID: 37154471
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.
Silverberg JI; Tallman AM; Ports WC; Gerber RA; Tan H; Zielinski MA
Acta Derm Venereol; 2020 Jun; 100(13):adv00170. PubMed ID: 32318744
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
Callender VD; Alexis AF; Stein Gold LF; Lebwohl MG; Paller AS; Desai SR; Tan H; Ports WC; Zielinski MA; Tallman AM
Am J Clin Dermatol; 2019 Oct; 20(5):711-723. PubMed ID: 31264114
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis.
Geng B; Hebert AA; Takiya L; Miller L; Werth JL; Zang C; Sanders P; Lebwohl MG
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1667-1678. PubMed ID: 34379285
[TBL] [Abstract][Full Text] [Related]
16. Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole.
Ständer S; Yosipovitch G; Bushmakin AG; Cappelleri JC; Luger T; Tom WL; Ports WC; Zielinski MA; Tallman AM; Tan H; Gerber RA
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1742-1746. PubMed ID: 31132182
[TBL] [Abstract][Full Text] [Related]
17. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.
Zane LT; Kircik L; Call R; Tschen E; Draelos ZD; Chanda S; Van Syoc M; Hebert AA
Pediatr Dermatol; 2016 Jul; 33(4):380-7. PubMed ID: 27193740
[TBL] [Abstract][Full Text] [Related]
18. Translating the Investigator's Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis.
Thyssen JP; Zang C; Neary MP; Bushmakin AG; Cappelleri JC; Cha A; Russo C; Luger TA
Dermatol Ther (Heidelb); 2021 Jun; 11(3):845-853. PubMed ID: 33728583
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis.
Ma L; Tao X; Liu S; Cheng H; Fang R; Zhao Y; Cha A; Encinas GA; Zhou Y; Deng Y; Zhang J
Dermatol Ther (Heidelb); 2024 May; 14(5):1229-1243. PubMed ID: 38748345
[TBL] [Abstract][Full Text] [Related]
20. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
Bissonnette R; Pavel AB; Diaz A; Werth JL; Zang C; Vranic I; Purohit VS; Zielinski MA; Vlahos B; Estrada YD; Saint-Cyr Proulx E; Ports WC; Guttman-Yassky E
J Allergy Clin Immunol; 2019 Nov; 144(5):1274-1289. PubMed ID: 31419544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
